



## Concept Development Form

Please ensure that your concept addresses the majority of points noted in the Concept Development Form below. A checklist is provided below to aid investigators in preparing their concept for submission to ANZGOG.

Concepts are reviewed by the Research Advisory Committee and the Consumer Research Panel.

Email to: [concepts@anzgog.org.au](mailto:concepts@anzgog.org.au)

Date of submission:	
Concept Title	
Study Phase	<input type="checkbox"/> Phase I <input type="checkbox"/> Phase II <input type="checkbox"/> Phase III <input type="checkbox"/> Other
Cancer Type	<input type="checkbox"/> Ovarian <input type="checkbox"/> Cervical <input type="checkbox"/> Endometrial <input type="checkbox"/> Other
Background and Significance	
Study Summary	Aims:
	Hypothesis:
	Objectives:
	Endpoints:
Subject Population	
Study Procedures	
Statistical Considerations	
Feasibility	
Biospecimen Collection /Translational Research	
Quality of Life Consideration	Yes (will be integrated into protocol) <input type="checkbox"/> No <input type="checkbox"/> If 'No', please provide reasoning:
Health Economics Consideration	Yes <input type="checkbox"/> No <input type="checkbox"/>
Funding	<input type="checkbox"/> Budget developed <input type="checkbox"/> Funded <input type="checkbox"/> Pending <input type="checkbox"/> None Funding options for consideration: <input type="checkbox"/> NHMRC/CA <input type="checkbox"/> Local Institution <input type="checkbox"/> ANZGOG <input type="checkbox"/> Other .....

Drugs and sponsorship	Drug: _____ Pharma Co: _____ Will pharma provide drug? Yes <input type="checkbox"/> No <input type="checkbox"/> N/A <input type="checkbox"/> Pharma contact information: _____
Lay summary for consumer review (250 words)	
List of other collaborative trial groups involved	
Protocol	In development: <input type="checkbox"/> Yes <input type="checkbox"/> No Assistance required from ANZGOG to develop further: <input type="checkbox"/> Yes <input type="checkbox"/> No
ANZGOG involvement requested	Multi-centre trial with ANZGOG Study Identification: <input type="checkbox"/> coordinated by the ANZGOG/CTC Collaboration <input type="checkbox"/> coordinated by another centre ..... <input type="checkbox"/> Other research study seeking ANZGOG Study Identification: Describe ..... <input type="checkbox"/> limited or single centre study ..... <input type="checkbox"/> Unknown, to be determined

### Study Chair

Name:	Organisation:
Speciality:	Email:
Phone:	Mobile:

### Investigator/s

Investigators' names should be supplied in the surname-last format with the initial in capital. Institutional affiliations should be indicated with superscript numbers following the author name. All affiliations should contain institution, city and country.

Example:

J Smith<sup>1</sup>, S Doe<sup>1</sup>

<sup>1</sup> Department of Oncology, XYZ Hospital, Sydney, Australia

<b>Investigator/s (list all)</b>
----------------------------------

## Affiliations (list all the institutions)

## Guidelines for completing your concept

### CONCEPT TITLE

- Should be in the PICO format (ie the title should hold information on the Participants, Intervention and Comparison groups, and the Outcomes of the trial).

### BACKGROUND AND SIGNIFICANCE

- Have you addressed the scientific validity?
- Is it an important question?
- Size of population defined?
- Sufficient rationale to proceed?
- Is it clinically relevant?
- Have you searched ANZCTR and other registries? [www.anzctr.org.au](http://www.anzctr.org.au)

### STUDY SUMMARY

- Aims:
  - i. Are they clearly stated?
- Trial objectives
  - ii. Do they match aims?
- Hypotheses:
  - iii. Are they clearly stated?
  - iv. Do they match aims and objectives?
- Endpoints:
  - i. Are they measurable?
  - ii. Are they suitable to answer trial questions?

### STUDY DESIGN AND STATISTICS

- Phase of study?
- Is design appropriate to address the question?
- Are treatment arms clearly described?
- What is the sample size estimate?
- Is the sample size justified in terms of primary endpoint?
- Is the study likely to detect a clinically significant difference?
- Has a statistician reviewed the study design?
- Is the study feasible? Outline the proposed sources of subjects and estimated recruitment rates.

### SUBJECT POPULATION

- Target population and setting should be described briefly. Main inclusion criteria – are they clearly stated and clinically relevant?

**STUDY INTERVENTION**

- Briefly describe actions to be taken

**FUNDING**

- Is there any financial support for the study?

**OTHER**

- Is there a translational research component?
- Have QOL and Health Economics assessments been included?
- Is there collaborative support from other trials groups